FDA estimates the burden of this collection of information as follows:

### TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN ¹

<table>
<thead>
<tr>
<th>Disclosure regarding additional risks in OTC prescription drug TV ads</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Total annual responses</th>
<th>Average burden per response</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilot Study Screener ..........</td>
<td>1700 (insomnia), 539 (high cholesterol), 3774 (depression).</td>
<td>1</td>
<td>6,013</td>
<td>0.03 (2 minutes)</td>
<td>180</td>
</tr>
<tr>
<td>Main Study Screener ..........</td>
<td>4252 (insomnia), 1347 (high cholesterol), 9433 (depression).</td>
<td>1</td>
<td>15,032</td>
<td>0.03 (2 minutes)</td>
<td>451</td>
</tr>
<tr>
<td>Pilot Study ..........................</td>
<td>600 (200 for each medical condition)</td>
<td>1</td>
<td>600</td>
<td>0.50 (30 minutes)</td>
<td>300</td>
</tr>
<tr>
<td>Main Study .........................</td>
<td>1500 (500 for each medical condition)</td>
<td>1</td>
<td>1500</td>
<td>0.50 (30 minutes)</td>
<td>750</td>
</tr>
<tr>
<td><strong>Total</strong> ............................</td>
<td>................................</td>
<td>................................</td>
<td>................................</td>
<td>................................</td>
<td><strong>1,681</strong></td>
</tr>
</tbody>
</table>

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: January 7, 2015.

Leslie Kux,  
Associate Commissioner for Policy.

[FR Doc. 2015–00269 Filed 1–12–15; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Committee on Organ Transplantation Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting:

**Name:** Advisory Committee on Organ Transplantation (ACOT).

**Date And Time:** January 27, 2015, from 12:30 p.m. to 4:30 p.m. Eastern Standard Time.

**Place:** The meeting will be via audio conference call and Adobe Connect Pro.

**Status:** The meeting will be open to the public.

**Purpose:** Under the authority of 42 U.S.C. Section 217a, Section 222 of the Public Health Service Act, as amended, and 42 CFR 121.12 (2000), ACOT was established to assist the Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. ACOT is composed of up to 25 members including the Chair. Members serve as Special Government Employees and have diverse backgrounds in fields such as organ donation, health care public policy, transplantation medicine and surgery, critical care medicine, and other medical specialties involved in the identification and referral of donors, non-physician transplant professions, nursing, epidemiology, immunology, law and bioethics, behavioral sciences, economics and statistics, as well as representatives of transplant candidates, transplant recipients, organ donors, and family members.

**Agenda:** The Committee will hear presentations including those on the following topics: Kidney Paired Donation, Vascularized Composite Allografts; the HOPE Act; and recommendations sent to the Secretary. Agenda items are subject to change as priorities indicate.

After Committee discussions, members of the public will have an opportunity to comment. Because of the Committee’s full agenda and timeframe in which to cover the agenda topics, public comment will be limited. All public comments will be included in the record of the ACOT meeting. Meeting summary notes will be posted on Department’s organ donation Web site at [http://www.organdonor.gov/legislation/ advisory.html#meetings](http://www.organdonor.gov/legislation/advisory.html#meetings).

The draft meeting agenda will be posted on [www.blsmeetings.net/ACOT](http://www.blsmeetings.net/ACOT). Those participating in this meeting should register by visiting [www.blsmeetings.net/ACOT](http://www.blsmeetings.net/ACOT). The deadline to register for this meeting is Monday, January 26, 2015. For all logistical questions and concerns, please contact Anita Allen, Seamon Corporation at 301–658–3442 or send an email to aallen@seamoncorporation.com.

The public can join the meeting by:

1. **(Audio Portion) Calling the Conference Phone Number (888–324–4391) and providing the Participant Code (2426); and**
2. **(Visual Portion) Connecting to the ACOT Adobe Connect Pro Meeting using the following URL and entering as GUEST:** [https://hrsa.connectsolutions.com/acot1](https://hrsa.connectsolutions.com/acot1) (copy and paste the link into your browser if it does not work directly, and enter as a guest).

Participants should call and connect 15 minutes prior to the meeting for logistics to be set up. If you have never attended an Adobe Connect meeting, please test your connection using the following URL: [https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm](https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm) and get a quick overview by following URL: [http://www.adobe.com/go/connectprooverview](http://www.adobe.com/go/connectprooverview). Call (301) 443–0437 or send an email to ptongele@hrsa.gov if you are having trouble connecting to the meeting site.

**Public Comment:** It is preferred that persons interested in providing an oral presentation email a written request, along with a copy of their presentation, to Patricia Stroup, MBA, MPA, Executive Secretary, Healthcare Systems Bureau, Health Resources and Services Administration, at pstripou@hrsa.gov. Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative.

The allocation of time may be adjusted to accommodate the level of expressed interest. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may request it during the public comment period. Public participation and ability to comment will be limited to time as it permits.

**FOR FURTHER INFORMATION CONTACT:**
Patricia Stroup, MBA, MPA, Executive
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; K-awards and R13 conference support review.

Date: February 25, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, DEM II, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Manana Sukhareva, Ph.D., Scientific Review Officer, 6707 Democracy Boulevard, Suite 959, Bethesda, MD 20892, 301–451–3397, sukharem@mail.nih.gov.

Dated: January 7, 2015.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–00292 Filed 1–12–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

Date: February 2, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Room 3E61, 5601 Fishers Lane, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Raymond R. Schleef, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/ NIAID, 5601 Fishers Lane, Rockville, MD 20852–7616, 240–669–5019, schlee@nih.gov.

Late notification due to delayed response from panel members.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research; National Institutes of Health, HHS)

Dated: January 7, 2015.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–00292 Filed 1–12–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Osteoporosis Fellowship Review.

Date: January 20, 2015.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).